"The US represents a significant opportunity for the company...

"The US represents a significant opportunity for the company with 120,000 tissue expander devices that are used each year and a total addressable market of over 350,000 devices per year."

the above was from their Aug '15 newsletter.....don't worry about any changes to the US health care system....even if 20% were removed because of health system changes, the market is still huge....from recent newsletter, roll out to 12 centres (those involved in initial approval/surgeons already trained), then roll out to 120+ centres in 2nd 1/2 of '17. They are ready to open up a second production line if needed. Capturing only 15% of the 120,000 device per year market max's out this first line.

The product is ground breaking....if a woman has a choice between going to a doctor for a saline injection into the implant as against using a remote control in privacy and the expansion of tissue is achieved as rapidly but less painfully due to smaller/more frequent enlargements...it's a no brainer....

If the product is $10,000, insurance or no insurance, many are going to simply pay for it, surely?

If the product is $10,000/device and they hit 1500-1600/mth by end of '17/early '18, then the company is doing $15m/mth in revenue ($180M/yr).....profit of 50%....pe of 10, mcap 900m, pe of 20, mcap 1.8B....plug in your own numbers but the company is headed north of 1B within 24mths and maybe sooner....and if numbers implanted climb each Q, then it may be one of those companies whose share price climbs year after year after year as revenues begin to be realised.

Their share price has bounced off the 1.05 to 1.10 level some 5 times in the past 12 months....and now the company has moved from product developer to manufacturer/distributor/revenue generator....that's why I started buying today and will keep buying as funds become available, as always....dyor

kind regards, SEAH.